Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
5(29%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
18%
Ph phase_3
1
6%
Ph not_applicable
6
35%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
6(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

17

all time

Status Distribution
Active(7)
Completed(6)
Other(4)

Detailed Status

Completed6
unknown4
Recruiting3
Not yet recruiting2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
17
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (30.0%)
Phase 31 (10.0%)
N/A6 (60.0%)

Trials by Status

unknown424%
not_yet_recruiting212%
completed635%
active_not_recruiting212%
recruiting318%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT06988007Not Applicable

Bone Arches: Performance of Pseudo-scanner Sequences in Segmenting the Extent of the Tumour and in Planning Surgical Resection Using the CT Scan as a Reference

Not Yet Recruiting
NCT07284082

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

Recruiting
NCT06931561Not Applicable

Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System

Recruiting
NCT02950987Not Applicable

Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes

Active Not Recruiting
NCT07230327

Whole Body MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Radiographic axSpA and Non-radiographic axSpA

Recruiting
NCT05353907

Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma

Not Yet Recruiting
NCT02815033Phase 2

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

Completed
NCT02814968Phase 2

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

Completed
NCT01737255

Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome

Completed
NCT03820778Not Applicable

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

Active Not Recruiting
NCT01464086Phase 3

LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)

Completed
NCT02966574Not Applicable

Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers

Unknown
NCT01883128Phase 2

FOcal RECurrent Assessment and Salvage Treatment

Unknown
NCT01993160Not Applicable

18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer

Completed
NCT00592462

Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases

Completed
NCT02935816

Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques

Unknown
NCT02935348

Whole Body PET-MRI in Paediatric and Adolescent Lymphoma

Unknown

All 17 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
17